Posted by Michael Wonder on 06 Dec 2016
Kite Pharma receives FDA breakthrough therapy designation for KTE-C19 for the treatment of refractory, aggressive non Hodgkin lymphoma
7 December 2015 - Kite Pharma today announced that the U.S. FDA has granted breakthrough therapy designation status to the Company's lead product candidate, KTE-C19, for the treatment of patients with refractory diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), and transformed follicular lymphoma (TFL).
KTE-C19 is an investigational therapy in which a patient's T cells are genetically modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias.
